Literature DB >> 34036137

Right upper quadrant cytoreductive procedures and cardiophrenic lymph node resection in primary debulkig surgery for ovarian cancer.

Joao Casanova1, José Filipe Cunha2.   

Abstract

Upfront debulking surgery followed by adjuvant chemotherapy still remains as the mainstay approach to patients with advanced ovarian cancer (Eisenhauer et al., 2006). Upper abdominal surgery is often required to achieve complete gross resection and there are several studies in the literature reporting increased survival, as well as a minimal but acceptable increase in morbidity, as a result of this shift in the surgical paradigm (Chi et al., 2009). Cardiophrenic lymph nodes (CPLNs), also referred to as paracardiac and supradiaphragmatic lymph nodes, are located just above the diaphragm. In diseases such as advanced ovarian cancer, where there is often considerable abdominal and peritoneal tumor burden, these lymph nodes can harbor metastases. These nodes are usually larger than 5 mm in diameter and are easily identified on computed tomography. Evidence suggests that this finding should not preclude primary debulking surgery (if resectable disease in the abdomen) as it is associated with an increased median overall survival even in stage IV disease (Cowan et al., 2017, Prader et al., 2016). We present a video highlighting one of the most commonly performed debulking procedures in the upper abdomen - right diaphragmatic peritoneal stripping (the patient had multiple small implants in both the diaphragmatic peritoneum and Morisońs Pouch peritoneum, so en bloc resection was performed) - followed by a transabdominal excision of an enlarged right cardiophrenic lymph node. The defect was closed with a 2-0 polypropylene running suture.
© 2021 The Authors.

Entities:  

Keywords:  Cardiophrenic lymph node; Debulking surgery; Right upper quadrant

Year:  2021        PMID: 34036137      PMCID: PMC8134990          DOI: 10.1016/j.gore.2021.100781

Source DB:  PubMed          Journal:  Gynecol Oncol Rep        ISSN: 2352-5789


Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

CRediT authorship contribution statement

Joao Casanova: Conceptualization, Supervision, Data curation, Formal analysis, Writing - original draft, Writing - review & editing. José Filipe Cunha: Conceptualization, Data curation, Formal analysis, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  4 in total

1.  The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

Authors:  Eric L Eisenhauer; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Elizabeth A Poynor; Carol Aghajanian; William R Jarnagin; Ronald P DeMatteo; Michael I D'Angelica; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2006-08-04       Impact factor: 5.482

2.  Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer.

Authors:  Sonia Prader; Philipp Harter; Christoph Grimm; Alexander Traut; Kai-Uwe Waltering; Pier Francesco Alesina; Sebastian Heikaus; Beyhan Ataseven; Florian Heitz; Stephanie Schneider; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2016-03-17       Impact factor: 5.482

3.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

4.  Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

Authors:  Renee A Cowan; Jill Tseng; Vijayashree Murthy; Radhika Srivastava; Kara C Long Roche; Oliver Zivanovic; Ginger J Gardner; Dennis S Chi; Bernard J Park; Yukio Sonoda
Journal:  Gynecol Oncol       Date:  2017-09-06       Impact factor: 5.482

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.